BioStock: BioInvent’s BI-1808 gains broad FDA support

BioInvent has secured a win with the FDA granting Orphan Drug Designation to BI-1808 for T-cell lymphoma (TCL), a broad category covering multiple subtypes, including cutaneous T-cell lymphoma (CTCL). This news, paired with previously disclosed promising early data, arrives as the company anticipates further BI-1808 data by mid-2025, with additional readouts expected from its portfolio of six ongoing clinical programs throughout the year.

Read the article at biostock.se:

https://www.biostock.se/en/2025/03/bioinvents-bi-1808-gains-broad-fda-support/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/